Glycoprotein 41 (Gp41) Pipeline with Analysis by Indications, Stage of Development and Mechanism of Action Reviewed H2 2017

Market Research Hub (MRH) has recently broadcasted a new study to its broad research portfolio, which is titled as “Glycoprotein 41 (gp41)-Pipeline Review, H2 2017”, report provides Glycoprotein 41 (gp41) - Gp41 or glycoprotein 41 is a transmembrane protein that contains several sites within its ectodomain that are required for infection of host cells. It is a subunit of the envelope protein complex of retroviruses. The interaction of gp41 fusion peptides with the target cell causes a formation of an intermediate structure which bridges and fuses the viral and host membranes together.

Request For Free Sample Report: https://www.marketresearchhub.com/enquiry.php?type=S&repid=1350036

Glycoprotein 41 (gp41) pipeline Target constitutes close to 19 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 1, 6 and 2 respectively. Similarly, the universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 1 and 5 molecules, respectively. Report covers products from therapy areas Infectious Disease which include indications Human Immunodeficiency Virus (HIV) Infections (AIDS).

The latest report Glycoprotein 41 (gp41) - Pipeline Review, H2 2017, outlays comprehensive information on the Glycoprotein 41 (gp41) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Glycoprotein 41 (gp41) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope

- The report provides a snapshot of the global therapeutic landscape for Glycoprotein 41 (gp41)
- The report reviews Glycoprotein 41 (gp41) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Glycoprotein 41 (gp41) targeted therapeutics and enlists all their major and minor projects
- The report assesses Glycoprotein 41 (gp41) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Glycoprotein 41 (gp41) targeted therapeutics
Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Glycoprotein 41 (gp41)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Glycoprotein 41 (gp41) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Browse Full Report with TOC: https://www.marketresearchhub.com/report/glycoprotein-41-gp41-pipeline-review-h2-2017-report.html

Table of Content:
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Glycoprotein 41 (gp41) - Overview 7
Glycoprotein 41 (gp41) - Therapeutics Development 8
Products under Development by Stage of Development 8
Products under Development by Therapy Area 9
Products under Development by Indication 10
Products under Development by Companies 11
Products under Development by Universities/Institutes 13
Glycoprotein 41 (gp41) - Therapeutics Assessment 15
Assessment by Mechanism of Action 15
Assessment by Route of Administration 16
Assessment by Molecule Type 18
Glycoprotein 41 (gp41) - Companies Involved in Therapeutics Development 20
Amunix Operating Inc 20
Frontier Biotechnologies Inc 20
InnaVirVax SA 21
Longevity Biotech Inc 21
Mymetics Corp 22
Navigen Inc 22
Osel Inc 23
Pharis Biotec GmbH 23
Glycoprotein 41 (gp41) - Drug Profiles 24
CPT-31 - Drug Profile 24
Product Description 24
Mechanism Of Action 24
R&D Progress 24
DS-007 - Drug Profile 25
Product Description 25
Mechanism Of Action 25
R&D Progress 25
Enfuvirtide-XTEN - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
FB-006M - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
HIV-1 vaccine - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
LBT-5001 - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
Monoclonal Antibodies to Target GP120 and GP41 for HIV - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
MYMV-101 - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
MYMV-201 - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
Recombinant Peptides for HIV-1 - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
Recombinant Protein to Inhibit Glycoprotein 41 and Glycoprotein 120 for Infectious Disease - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
Small Molecules to Target GP120 and Gp41 for HIV-1 Infections - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
STOP-3S - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
Synthetic Peptide to Target gp41 for HIV Infection - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
Synthetic Peptides to Inhbit GP41 for HIV Infections - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
Synthetic Peptides to Inhibit GP120, GP41, Tat, Integrase and Protease for HIV-1 Infection - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
VAC-02 - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
VAC-3S - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
VIR-576 - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
Glycoprotein 41 (gp41) - Dormant Products 48
Glycoprotein 41 (gp41) - Discontinued Products 50
Glycoprotein 41 (gp41) - Product Development Milestones 51
Featured News & Press Releases 51
Continue….

Enquire About This Report: https://www.marketresearchhub.com/enquiry.php?type=enquiry&repid=1350036

About Market Research Hub:

Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of pharmaceutical market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.
MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Contact Us

90 State Street,
Albany, NY 12207,
United States

Toll Free: 800-998-4852 (US-Canada)
Email: press@marketresearchhub.com
Website: http://www.marketresearchhub.com/
Read Industry News at - https://www.industrynewsanalysis.com/

This release was published on openPR.